A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples